Michael Drazer is an Assistant Professor in the Section of Hematology/Oncology at the University of Chicago. He was raised on a family farm before graduating from Indiana University with degrees in Biochemistry, Biology, and English. He earned an MD and a PhD in Human Genetics from the University of Chicago. He cares for patients with hereditary blood disorders and hereditary cancer syndromes as a member of the Hematology, Leukemia, Stem Cell Transplant/Cellular Therapy, Mesothelioma, Myeloma, and Cancer Risk programs at UChicago. He is a trainer in the Human Genetics PhD program at UChicago. He also serves as the Associate Program Director of the Physician Scientist Development Program in the Department of Medicine, where he is responsible for directing the development of physician scientists pursuing accelerated residency and fellowship training.
Outside of the lab and hospital, you can find him running long distances through the woods of the Midwest and up/down the mountains of the western United States.
Indiana University
Bloomington
BA, BS - Biochemistry; Biology; English
University of Chicago
Chicago
PhD - Human Genetics
University of Chicago
Chicago
MD - Medicine
University of Chicago
Chicago
Residency - Internal Medicine
University of Chicago
Chicago
Fellowship - Hematology/Oncology
Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitors.
Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitors. Haematologica. 2026 Jan 29.
PMID: 41609051
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies.
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347.
PMID: 41139955
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
PMID: 40813576
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma.
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma. Leukemia. 2025 Sep; 39(9):2285-2288.
PMID: 40670674
ANKRD26-related thrombocytopenia 2 with a baseline increase in blasts: implications for clinical surveillance.
ANKRD26-related thrombocytopenia 2 with a baseline increase in blasts: implications for clinical surveillance. Blood. 2025 Jul 10; 146(2):254-259.
PMID: 40331912
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy.
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
PMID: 40521395
Video Education in Germline Genetic Testing: A Step Toward Improved Access to Personalized Medicine.
Video Education in Germline Genetic Testing: A Step Toward Improved Access to Personalized Medicine. JCO Oncol Pract. 2025 Nov; 21(11):1549-1551.
PMID: 40472277
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants.
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants. Leukemia. 2025 Jul; 39(7):1702-1713.
PMID: 40335619
Germ line JAK2 variants and hereditary blood cancers.
Germ line JAK2 variants and hereditary blood cancers. Blood Adv. 2025 Apr 08; 9(7):1585-1586.
PMID: 40152887
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights.
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights. JCO Oncol Pract. 2025 Oct; 21(10):1413-1416.
PMID: 40053896